ERbeta Agonists Inhibit Squamous Cell Carcinoma Proliferation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Squamous cell carcinomas are resistant to conventional and targeted drug treatments, and there is a lack of understanding in the direct transcriptional control of the Notch1 gene, which is crucial for tumor suppression in these cancers.

Innovation Solution

Identification of Egr3, Dlx5, and ERβ as direct regulators of Notch1 gene expression, with ERβ acting as a positive determinant that, when increased, promotes Notch1 expression and squamous differentiation, and the use of ERβ agonists to inhibit cancer cell proliferation.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional and targeted drug treatments are used, then treatment resistance occurs in squamous cell carcinomas, but the patent identifies a new therapeutic approach through ERβ agonists that can overcome this resistance by promoting Notch1 expression and cell differentiation

Engineering Contradiction:

Improvetreatment effectivenessVSAvoiddrug resistance

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

Instead of inhibiting Notch1 as is conventional in cancer therapy, this patent inverts the approach by activating Notch1 through ERβ agonists. The patent demonstrates that ERβ agonists increase Notch1 expression and promote differentiation in squamous cell carcinomas, reversing the typical inhibition strategy and overcoming drug resistance.

Inventive Principle:

Principle #13The other way round (Inversion)

Solution Approach 2:

The patent changes the regulatory parameter of Notch1 from suppressed to activated state by introducing ERβ agonists. This parameter change transforms the cellular response from proliferation to differentiation, thereby overcoming treatment resistance in squamous cell carcinomas.

Inventive Principle:

Principle #35Parameter changes

2Loss of information

If there is a lack of understanding in direct transcriptional control of Notch1, then targeted therapy is limited, but the patent identifies specific transcription factors (Egr3, Dlx5, ERβ) that directly regulate Notch1 expression

Engineering Contradiction:

Improveunderstanding of transcriptional controlVSAvoidtherapeutic targeting complexity

Core Design Contradiction:

Loss of informationVSDevice complexity

Solution Approach 1:

The patent identifies ERβ as an intermediary transcription factor that directly binds to the Notch1 promoter region and activates its expression. This intermediary mechanism provides a clear therapeutic target (ERβ) that mediates the effect on Notch1, simplifying the therapeutic approach despite the complexity of transcriptional control.

Inventive Principle:

Principle #24Intermediary (Mediator)

3Productivity

If Notch1 activation is promoted through ERβ agonists, then cell differentiation is enhanced and proliferation is inhibited, but this requires precise control of gene expression levels

Engineering Contradiction:

Improvecell differentiation rateVSAvoidgene expression control

Core Design Contradiction:

ProductivityVSManufacturing precision

Solution Approach 1:

The patent utilizes the endogenous ERβ-Notch1 feedback loop where ERβ agonists activate Notch1 expression, which in turn can regulate ERβ activity. This feedback mechanism provides automatic control of gene expression levels, ensuring precise differentiation without requiring external precision control.

Inventive Principle:

Principle #23Feedback

Data Source

PatentUS10188747B2Methods and compositions for the treatment of cancer

Publication Date: 2019.01.29 THE GENERAL HOSPITAL CORP

AI summary

The technology described herein is directed to agonists of, e.g. Esr2, Dlx5, and/or Egr3, for the inhibition of cancer cells (e.g. squamous carcinoma cancer cells) and the treatment of cancer.